Wellgistics Strengthens PharmacyChain(TM) with Insurance Eligibility & Benefits Verification Capabilities

Rhea-AI Summary

Wellgistics (NASDAQ:WGRX) secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV), making the service available immediately via its EinsteinRx AI hub and preparing integration into PharmacyChain later in 2026.

Management expects EBV to contribute to a new revenue stream beginning in Q2 2026 and highlights cost reductions for its own pharmacy as it rolls out GLP-1 and Forzet weight-loss offerings. The EBV market is cited at $2.39B in 2025 growing to $3.0B by 2030.

Positive

• Secured preferred EBV pricing available immediately via EinsteinRx
• Company expects EBV to become a revenue stream starting Q2 2026
• Cited EBV market growth from $2.39B (2025) to $3.0B (2030)

Negative

• Providers must still pay an out-of-pocket fee per EBV request, which may limit adoption

Argus Mar 11 session

+5.38% close to close Open Argus

Details

News Market Reaction – WGRX

On Mar 11, the day this news came out, WGRX closed 5.38% above the previous close.

Data tracked by StockTitan Argus for the Mar 11 session.

Key Figures

Share price: $0.182 24h price change: 4.18% Volume today: 2,175,193 shares +5 more

Share price

$0.182

Pre-news trading level for WGRX

24h price change

4.18%

Move during prior 24 hours before this article

Volume today

2,175,193 shares

Compared with 20-day average volume of 1,837,421

Volume vs avg

1.18x

Relative to 20-day average volume

52-week high

$7.04

52-week trading range high for WGRX

52-week low

$0.157

52-week trading range low for WGRX

Market cap

$17,869,996

Pre-news equity value based on latest price

EBV market size 2025

$2.39 billion

Global medical insurance EBV market in 2025, per article

Historical Context

5 past events · Latest: Mar 09

5 events

1. Mar 09

   Product launch

   24h Move

   +5.8%

   Launch of Forzet medical food for GLP-1-associated muscle loss via pharmacy channels.

2. Mar 05

   Platform development

   24h Move

   -9.2%

   Selection of five blockchain platforms to build PharmacyChain serialization system.

3. Feb 23

   Partnership expansion

   24h Move

   +9.8%

   Expanded Datavault AI partnership for HaaS smart contracts and tokenized patient data.

4. Feb 18

   Strategic investment

   24h Move

   +0.3%

   Investment in mental health AI startup to enhance EinsteinRx and patient engagement.

5. Feb 11

   Partnership expansion

   24h Move

   +4.0%

   Tollo Health partnership expansion adding telehealth and mental health AI to platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

eligibility and benefits verification, ebv, artificial intelligence, ai, +3 more

7 terms

eligibility and benefits verification medical

"Medical insurance eligibility and benefits verification (EBV) is a core health techn..."

Eligibility and benefits verification is the routine check that confirms whether a patient’s health plan will cover a proposed medical service and what portion it will pay. For investors, it matters because this process reduces the risk of unpaid bills or surprise costs, improves cash flow predictability for healthcare providers, and affects revenue timing and margins—much like confirming a store accepts your payment method and coupon before you buy.

ebv medical

"Medical insurance eligibility and benefits verification (EBV) is a core health techn..."

Epstein-Barr virus (EBV) is a common human virus that can cause infectious mononucleosis and is linked to certain cancers and chronic conditions; think of it as a long-lived guest in the body that can sometimes trigger serious health problems. Investors watch EBV closely in biotech and healthcare because treatments, vaccines, or diagnostics aimed at the virus can drive clinical trial outcomes, regulatory decisions, and future revenue potential, while failures or safety issues can affect company valuations and risk profiles.

artificial intelligence technical

"dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its p..."

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

ai technical

"dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its p..."

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

blockchain-enabled smart contracts technical

"its patented blockchain-enabled smart contracts platform PharmacyChain™, today annou..."

Blockchain-enabled smart contracts are self-executing agreements stored on a digital ledger that automatically enforce their terms when certain conditions are met. They function like digital vending machines: once the predefined rules are satisfied, the contract completes without needing a third party. For investors, these contracts can reduce costs, increase transparency, and ensure transactions happen reliably and instantly.

smart contracts technical

"the 'health technology railroad' smart contracts that will govern the serialization..."

Self-executing digital agreements whose terms are written as code and stored on a distributed ledger so they run automatically when preset conditions are met — like a vending machine that releases a snack only after you insert the right coins. Investors care because smart contracts can speed up transactions, cut middlemen, reduce errors and fraud, and create new ways to issue, trade or enforce financial assets, which affects costs, risk and regulatory oversight.

View in glossary

glp-1 medical

"begin the rollout of our GLP-1 and Forzet™ weight loss offering."

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Medical insurance eligibility and benefits verification (EBV) is a core health technology capability necessary for PharmacyChain™ to gain market adoption

• EBV services offering enabled with preferred pricing being made immediately available to providers, partners and the Wellgistics Pharmacy Network

• EBV market expected to grow from $2.39 billion in 2025 to $3 billion in 2030 according to The Business Research Company¹

TAMPA, FL / ACCESS Newswire / March 11, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV) that enables PharmacyChain for providers, partners and pharmacies in order to facilitate its faster adoption into the US healthcare ecosystem. EBV is crucial because it allows companies that engage in the distribution of medical products and services to know whether a particular product or service is covered by a patient's insurance carrier and the level of coverage that patient has. This information is paramount to understand provider reimbursement levels and out-of-pocket costs for patients. Each time a provider requests EBV information, they must pay an out-of-pocket fee. Wellgistcs is making preferred pricing on this service available to providers, partners and its Wellgistics Pharmacy Network immediately through its EinsteinRx AI hub platform in preparation for integration into PharmacyChain later this year.

"Getting preferred pricing access to EBV is a major win for Wellgistics," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics. "It allows to immediately open up a new revenue stream with the exact customers and partners that will eventually utilize our PharmacyChain smart contracts solution, in addition to reducing our costs for the Company's own pharmacy as we begin the rollout of our GLP-1 and Forzet™ weight loss offering. The pricing certainty this adds to PharmacyChain allows us to code with confidence as we build the 'health technology railroad' smart contracts that will govern the serialization of the drug distribution supply chain, from manufacturer to patient. We are gaining momentum around our health technology stack and look forward to making EBV a meaningful component of our revenue stream beginning in the second quarter of 2026."

The market for medical insurance eligibility and benefits verification is expected to grow from $2.39 billion in 2025 to $3 billion in 2030 according to The Business Research Company¹. Growth expectations are being attributed to rising US healthcare billing complexity, increasing insurance claim denial rates, expansion of digital health records usage, growing need for revenue cycle optimization and increased administrative burden on providers.

Parties interested in speaking with Wellgistics about medical insurance eligibility and benefits verification² can contact the Company at info@wellgisticshealth.com

¹https://www.thebusinessresearchcompany.com/report/insurance-eligibility-verification-global-market-report
²https://wellgisticshub.pharmacy/

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may include, without limitation, statements regarding the anticipated launch, availability, distribution, commercialization and potential adoption of Forzet™, the expected benefits of the product, the Company's plans to integrate Forzet into its pharmacy network and telehealth offerings, the development and expansion of the Company's direct-to-consumer initiatives, and the potential growth of the GLP-1 agonist market. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "continue," or the negative of these terms or other comparable terminology.

Forward-looking statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, risks related to the commercialization and market acceptance of the Company's products and services, the Company's ability to successfully expand its pharmacy network and telehealth initiatives, regulatory and compliance considerations relating to medical foods and healthcare products, competition in the healthcare and pharmaceutical distribution markets, changes in market conditions, and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The Company makes no representation that Forzet™ is intended to diagnose, treat, cure, or prevent any disease.

Wellgistics Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Wellgistics (WGRX) announce about EBV on March 11, 2026?

They secured contractual rights to preferred EBV pricing and enabled immediate access via EinsteinRx. According to the company, this prepares EBV integration into PharmacyChain later in 2026 and aims to accelerate market adoption.

When will Wellgistics (WGRX) expect EBV to generate revenue?

Wellgistics expects EBV to contribute revenue beginning in Q2 2026. According to the company, preferred pricing is available now through EinsteinRx while PharmacyChain integration is planned later in 2026.

How large is the EBV market cited by Wellgistics (WGRX)?

The company cites EBV market growth from $2.39 billion in 2025 to $3.0 billion by 2030. According to the company, growth is driven by billing complexity and rising demand for revenue cycle tools.

How will EBV access be delivered to providers and partners of Wellgistics (WGRX)?

EBV preferred pricing is being offered immediately through the EinsteinRx AI hub. According to the company, PharmacyChain integration is planned later in 2026 to expand distribution to partners and pharmacies.

Will providers still incur fees for EBV despite Wellgistics' preferred pricing?

Yes; providers must still pay an out-of-pocket fee per EBV request even with preferred pricing. According to the company, preferred pricing reduces costs but does not eliminate per-request fees for providers.